China is on the verge of integrating brain-computer interface (BCI) technology into everyday public applications within the next three to five years, a prominent expert in the field. This development signals a significant leap forward as Beijing intensifies efforts to close the gap with American startups, including Elon Musk’s Neuralink, which have been pioneering BCI advancements globally. The Chinese government recently underscored the importance of BCIs by designating them as a strategic industry in its latest five-year plan, placing the technology alongside other cutting-edge sectors such as quantum computing, embodied artificial intelligence, 6G telecommunications, and nuclear fusion.
Yao Dezhong, who directs the Sichuan Institute of Brain Science, shared insights during an interview held on the sidelines of China’s annual parliamentary sessions in Beijing. He emphasized that while new policies will not produce immediate results, the coming years will witness the gradual emergence of practical BCI products accessible to the general population. This timeline reflects the maturation of the technology from experimental stages to real-world applications, marking a critical phase in China’s ambitious push to become a global leader in neurotechnology.
China’s commitment to advancing BCIs is further illustrated by its national development strategy unveiled last year, which sets clear targets for achieving major technical breakthroughs by 2027. The plan also aims to nurture two to three world-class BCI companies by 2030, highlighting the country’s long-term vision for dominating this transformative industry. Notably, China stands as the second nation worldwide to initiate invasive BCI human trials, with over ten active studies currently underway—matching the scale of similar efforts in the United States. This year alone, researchers intend to enroll more than 50 patients across the country, underscoring the rapid expansion of clinical research in this domain.
Recent high-profile trials have demonstrated promising outcomes, enabling individuals with paralysis or limb amputations to regain partial mobility and control robotic prosthetics or intelligent wheelchairs through direct brain signals. Such breakthroughs not only showcase the potential of BCIs to revolutionize medical treatment but also highlight the growing integration of these technologies into China’s healthcare system. In fact, some BCI-based therapies have already been incorporated into national medical insurance schemes within pilot provinces, reflecting government support for wider accessibility. Market analysts project that the domestic BCI sector could reach a valuation of 5.58 billion yuan (approximately $809 million) by 2027, signaling robust economic prospects for this emerging field.
Yao pointed out several key advantages that position China favorably in the global BCI race. These include the country’s vast population, which creates substantial patient demand, a cost-effective industrial supply chain, and a rich pool of STEM (science, technology, engineering, and mathematics) talent. Moreover, the government is actively working to bridge the significant divide between scientific research, industrial development, and clinical application through policies such as insurance coverage expansion and the establishment of national standards. Despite these efforts, Yao acknowledged that transitioning from experimental research to clinical trials remains a lengthy and challenging process. To accelerate progress, many Chinese hospitals have established dedicated BCI research laboratories, fostering closer collaboration between medical practitioners and scientists.
In terms of technological approaches, Chinese researchers are exploring a diverse range of BCI modalities, including invasive, semi-invasive, and non-invasive systems, each with distinct clinical potentials. While U.S. companies like Neuralink focus primarily on invasive implants that penetrate brain tissue, China’s broader strategy aims to develop safer and more versatile options. Semi-invasive BCIs, which rest on the brain’s surface, offer a compromise by potentially reducing risks such as tissue damage and post-surgical complications, albeit with some loss in signal fidelity. Neuralink’s advanced surgical robot, capable of implanting hundreds of electrodes within minutes, represents a remarkable technical achievement. Yao praised this innovation but also highlighted China’s rapid advancements in the field, stating that the capabilities pursued by Musk’s company are increasingly attainable within the domestic research landscape.
As China accelerates its efforts to harness brain-computer interface technology, the coming years are expected to witness transformative changes in both medical treatment and human-machine interaction. The country’s strategic investments, combined with its unique advantages, position it to become a formidable player in this frontier of science and technology, potentially reshaping how humans interact with machines and overcome neurological disabilities.
